Posts - CLL Support | HealthUnlocked

Administrator•13 hours ago

Here's a welcome article that explains all about BTK degraders; the next class of BTK drug after the success of the FDA approved covalent BTKis...

BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL

Here's a welcome article that explains all about BTK degraders; the next class o...

Administrator•13 hours ago

[EDIT: I've purposely left this post Public so that other internet users can find it.] I like Microsopft Copilot, because it's built into my PC...

A cautionary tale about using AI

[EDIT: I've purposely left this post Public so that other internet users can fin...

SeymourB

•3 days ago

50 Replies

Want to take advantage of all our features? Just log in!

Moving closer to more affordable CAR-T therapy for cancers

CAR-T therapy has been used most successfully to treat some of the more acute blood cancers, less so in treating CLL and with limited success in solid tumours....

CAR-T therapy has been used most successfully to treat some of the more acute bl...

bennevisplace

•9 days ago

A fairly common observation of those taking the BTK inhibitor ibrutinib is that their hair can become curly or straight, or much more annoyingly, their nails...

Why does ibrutinib cause nail brittleness (onychorrhexis and onychoschizia) or curly hair in some CLL patients? What can you do about it?

A fairly common observation of those taking the BTK inhibitor ibrutinib is that ...

Administrator•21 days ago

On 6 January 2025, the journal BJ Haem published a review article titled Management strategies for patients with chronic lymphocytic leukaemia...

Review article summarises management strategies for those with CLL harbouring complex karyotype

On 6 January 2025, the journal BJ Haem published a review article titled Managem...

Administrator•1 month ago

Pirtobrutinib is the first FDA approved non-covalent BTK inhibitor (BTKi) for the treatment of CLL. The previously approved BTKi drugs (acalabrutinib,...

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)

Pirtobrutinib is the first FDA approved non-covalent BTK inhibitor (BTKi) for th...

In the past ten years, there has been a shift away from treating CLL/SLL with chemoimmunotherapy to treating it with more targeted therapies. To support...

Administrator•2 months ago

22 Replies

Consensus recommendations for CLL/SLL treatment selection and sequencing in the US

In the past ten years, there has been a shift away from treating CLL/SLL with ch...

Administrator•3 months ago

hi, I’m starting CLL treatment this week due to very low haemaglobin count. This will start with obinutuzumab with venetoclax to be added in 3 weeks. Are...

Initial Treatment - obinutuzumab And Venetoclax

hi, I’m starting CLL treatment this week due to very low haemaglobin count. Thi...

Theplodder

•3 months ago

12 Replies

Brukinsa with normal FISH, NOTCH1 and CD38-

Hi all Diagnosed since this past June. Started on Brukinsa due to 6mm Supraclavicular node. Tolerating well on reduced dose of 240mg. I have a Notch 1 mutation...

Hi all Diagnosed since this past June. Started on Brukinsa due to 6mm Supraclavi...

Reetywell71

•5 months ago

27 Replies

Real-world incidence and prevention of tumor lysis syndrome (TLS) in chronic lymphocytic leukemia (CLL) treated with venetoclax. From MSK

A few members who have been recommended ventoclax/Venclexta treatment, have posted about their concerns of developing Tumor Lysis Syndrome (TLS). So hopefully...

A few members who have been recommended ventoclax/Venclexta treatment, have post...

Hi There, Finnish 4th course of Rituximab over a week ago,would like to know what to expect after it,ha sore throat,mouthfuls of ulcers,getting pain down in my...

Administrator•6 months ago

11 Replies

What to expect after finishing course of rituximab

Hi There, Finnish 4th course of Rituximab over a week ago,would like to know wha...

Jsceltic67

•7 months ago

A Young Mom Confronts “Skyrocketing White Blood Cell Counts”...

Brave young kiwi woman

Kiwidi

•7 months ago

3 Replies

obinutuzamab fatigue

I had my second infusion of Obi Friday. All went well with no reaction. Had some sleeping issues from steroids but that has passed. Curious if people...

I had my second infusion of Obi Friday. All went well with no reaction. Had so...

Nbk59ct

•8 months ago

3 Replies

MRD - Flow test compared to clonoSEQ

I just got this result after a year of Acalabrutinib and Venetoclax on the Majic trial. I'm currently waiting for the clonoSEQ MRD6 results. Below...

I just got this result after a year of Acalabrutinib and Venetoclax on the Majic...

JDG45

•8 months ago

6 Replies

uMRD question

uMRD is great, but for a majority that reach it, CLL will inevitably reoccur, and at that point, because of the strong selective pressures put on the surviving...

uMRD is great, but for a majority that reach it, CLL will inevitably reoccur, an...

PulsedTherapy

•9 months ago

120 Replies

Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Phase 2 CLL2-BAAG trial results from the German CLL Study Group

Some very encouraging news for those with unmutated IGHV and/or TP53 aberrations, who are wondering how they will fare with a subsequent treatment. This phase...

Some very encouraging news for those with unmutated IGHV and/or TP53 aberrations...

Administrator•10 months ago

Introducing the Phase I EUPLAGIA-1 study (EudraCT 2021-003815-25), which investigated GLPG5201, a CD19 CAR T-cell therapy, in relapsed/refractory (R/R)...

Encouraging phase 1 trial results for GLPG5201, a CAR T-cell therapy

Introducing the Phase I EUPLAGIA-1 study (EudraCT 2021-003815-25), which investi...

bennevisplace

•10 months ago

For the Majic trail, arm "A", I would like to know if anyone has completed the first 15 cycles of Acalabrutinib and Venetoclax. Has your bone marrow testing...

Majic trial arm "A"

For the Majic trail, arm "A", I would like to know if anyone has completed the f...

JDG45

•11 months ago

12 Replies

A potential game-changer for CAR T cell therapy: mutations in cancer engineered to beat cancer

CAR T therapy has been successful in some acute blood cancers. Response rates, however, are considerably lower in CLL and solid tumours, with T cell exhaustion...

CAR T therapy has been successful in some acute blood cancers. Response rates, h...

bennevisplace

•1 year ago

It’s official I have completed 6 years of taking part in the I. & R Arm of the Flair Trial today . I started on 28th January 2018 and I took my last dose of...

Flair Trial Completed

It’s official I have completed 6 years of taking part in the I. & R Arm of the...

Sanphil

•1 year ago

A Phase II sub-study of SUPERNOVA clinical trial (2023) is currently operating to test the efficacy and safety of AZD3152 as a component of a reformulated...

Current SUPERNOVA Clinical Trial for Reformulated EVUSHELD for preventing COVID-19 infection for immune-impaired individuals

A Phase II sub-study of SUPERNOVA clinical trial (2023) is currently operating t...

Classicaljazz

•1 year ago

5 Replies

How you can help make ibrutinib plus venetoclax fixed duration therapy a reality for Australians with previously untreated CLL

In Australia, no new medicine can be listed on the Pharmaceutical Benefits Scheme (PBS) unless it has first been recommended by the Pharmaceutical Benefits...

In Australia, no new medicine can be listed on the Pharmaceutical Benefits Schem...

https://newsletters.drugs.com/l/HXdBAPWpNu8924jmwPHb3VvA/LQCEtlvhvlnyLNQoIP4Gfw/jLVV3dtGc2BI8hLRqrMq892g "Although the overall benefits of these products...

Administrator•1 year ago

6 Replies

Drugs.com FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed (CAR) T cell Immunotherapies

https://newsletters.drugs.com/l/HXdBAPWpNu8924jmwPHb3VvA/LQCEtlvhvlnyLNQoIP4Gfw/...

JerrysGirl3

•1 year ago

Hi All, There is a new targeted drug in Clinical Trials that may offer a new treatment option for us CLLers—Nemtabrutinib. For the entire article on this...

A new kid on the block? Nemtabrutinib

Hi All, There is a new targeted drug in Clinical Trials that may offer a new tr...

Varney

•1 year ago

18 Replies

Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis

The meta-analysis of 20 studies on CLL/SLL patients treated with new-generation BTKis was based on papers selected from "A comprehensive search on PubMed,...

The meta-analysis of 20 studies on CLL/SLL patients treated with new-generation ...

In more good news, today the Pharmaceutical Benefits Scheme (PBS) in Australia added venetoclax to its listings for the retreatment of CLL/SLL in those whose...

Administrator•1 year ago

17 Replies

Venetoclax has been added to the Pharmaceutical Benefits Scheme in Australia for use as a retreatment for CLL/SLL

In more good news, today the Pharmaceutical Benefits Scheme (PBS) in Australia a...

Administrator•1 year ago

Australia's Pharmaceutical Benefits Scheme (PBS) today added Zanubrutinib as a first line therapy for the treatment of CLL/SLL. As well as being available...

Zanubrutinib has been listed on the Pharmaceutical Benefits Scheme in Australia as a first line treatment for CLL/SLL

Australia's Pharmaceutical Benefits Scheme (PBS) today added Zanubrutinib as a f...

Administrator•1 year ago

We've had several posts in the last 24 hours about the U.S. government's plans to negotiate a price for ibrutinib. I mentioned...

Largest real world study of acalabrutinib and ibrutinib over 3 years, shows acalabrutinib has improved discontinuation rates

We've had several posts in the last 24 hours about the U.S. government's plans t...

Administrator•1 year ago